3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with ergotamine in 1 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (ergotamine) | Trials (ergotamine) | Recent Studies (post-2010) (ergotamine) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 2,352 | 103 | 103 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | ergotamine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.056 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 6.499 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.16 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.761 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 4.142 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0021 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0043 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0038 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.012 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0008 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 1.728 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.064 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.049 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0065 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.056 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0008 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0043 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0035 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrari, MD; Saxena, PR; van Royen, EA; Verhoeff, NP; Visser, WH | 1 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and ergotamine
| Article | Year |
|---|---|
Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier?
Topics: Benzamides; Blood-Brain Barrier; Brain; Contrast Media; Dopamine D2 Receptor Antagonists; Ergotamine; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Migraine Disorders; Pyrrolidines; Receptors, Dopamine D2; Substance Withdrawal Syndrome; Substance-Related Disorders; Tomography, Emission-Computed, Single-Photon | 1993 |